Crysvita is a medicine used for the treatment of X-linked hypophosphataemia, a hereditary disorder characterised by low levels of phosphate in the blood (hypophosphataemia). Phosphate is essential to build bones and teeth and to maintain their strength, so patients may develop rickets and other bone deformities and growth problems. Crysvita contains the active substance burosumab.
CRYSVITA (BUROSUMAB-TWZA) INDICATIONS:
CRYSVITA is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.
DOSAGE FORM & STRENGTH:
Crysvita 10mg/ml wholesaler, distributor
Crysvita 20mg/ml wholesaler, distributor
Crysvita 30mg/ml wholesaler, distributor
Rasso Swiss Pharma is a Crysvita (burosumab-twza)wholesaler distributor, supplier.